A preliminary targeted proteome approach using reverse phase protein arrays profiled 31 OCCC tumor samples with known ARID1A mutational status using 116 antibodies and observed differential expression of pAKT-Thr308 (23). This evidence concerns the gene ARID1A and neoplasm.